{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:47:16Z","timestamp":1770749236598,"version":"3.50.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>One of the most common autosomal dominant disorders is familial hypercholesterolemia (FH), causing premature atherosclerotic cardiovascular diseases and a high risk of death due to lifelong exposure to elevated low-density lipoprotein cholesterol (LDL-C) levels. FH has a proven arsenal of treatments and the opportunity for genetic diagnosis. Despite this, FH remains largely underdiagnosed worldwide. Cascade screening is a cost-effective method for the identification of new patients with FH and the prevention of cardiovascular diseases. It is usually based only on clinical data. We describe a 48-year-old index patient with a very high LDL-C level without controlled guidelines-based medication, premature atherosclerosis, and a rare variant in the low-density lipoprotein receptor (<jats:italic>LDLR<\/jats:italic>) gene. Phenotypic cascade screening identified three additional FH relatives, namely the proband's daughter, and two young grandsons. The genetic screening made it possible to rule out FH in the proband's younger grandson. This clinical case demonstrates that genetic cascade screening is the most effective way of identifying new FH cases. We also first described in detail the phenotype of patients with a likely pathogenic variant <jats:italic>LDLR<\/jats:italic>-p.K223_D227dup.<\/jats:p>","DOI":"10.3389\/fcvm.2022.982607","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T10:20:51Z","timestamp":1661422851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Phenotypic vs. genetic cascade screening for familial hypercholesterolemia: A case report"],"prefix":"10.3389","volume":"9","author":[{"given":"Anastasia V.","family":"Blokhina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra I.","family":"Ershova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey N.","family":"Meshkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna V.","family":"Kiseleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina V.","family":"Klimushina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia A.","family":"Zharikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeniia A.","family":"Sotnikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasily E.","family":"Ramensky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oxana M.","family":"Drapkina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat Rev Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation."},{"key":"B3","doi-asserted-by":"publisher","first-page":"840797","DOI":"10.3389\/fgene.2022.840797","article-title":"Familial hypercholesterolemia prevalence among ethnicities-systematic review and meta-analysis","volume":"13","author":"Toft-Nielsen","year":"2022","journal-title":"Front Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5551\/jat.CR003","article-title":"Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017","volume":"25","author":"Harada-Shiba","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"B7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B8","volume-title":"Clinical Guidelines and Evidence Review for Familial Hypercholesterolaemia: the Identification and Management of Adults and Children with Familial Hypercholesterolaemia","author":"DeMott","year":"2008"},{"key":"B9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.gim.2021.09.012","article-title":"The clinical genome resource (ClinGen) familial hypercholesterolemia variant curation expert panel consensus guidelines for LDLR variant classification","volume":"24","author":"Chora","year":"2022","journal-title":"Genet Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2003.11.010","article-title":"Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia","volume":"173","author":"Civeira","year":"2004","journal-title":"Atherosclerosis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1158\/0008-5472.CAN-17-0337","article-title":"Variant review with the integrative genomics viewer","volume":"77","author":"Robinson","year":"2017","journal-title":"Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/jpm11060464","article-title":"The prevalence of heterozygous familial hypercholesterolemia in selected regions of the Russian federation: the FH-ESSE-RF study","volume":"11","author":"Meshkov","year":"2021","journal-title":"J Pers Med."},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1253\/circj.CJ-21-0193","article-title":"Effect of cumulative exposure to low-density lipoprotein-cholesterol on cardiovascular events in patients with familial hypercholesterolemia","volume-title":"Circ J","author":"Tada","year":"2021"},{"key":"B17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.atherosclerosis.2008.07.005","article-title":"Update of Japanese common LDLR gene mutations and their phenotypes: mild type mutation L547V might predominate in the Japanese population","volume":"203","author":"Miyake","year":"2009","journal-title":"Atherosclerosis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/genes12010066","article-title":"The LDLR, APOB, and PCSK9 variants of index patients with familial hypercholesterolemia in Russia","volume":"12","author":"Meshkov","year":"2021","journal-title":"Genes"},{"key":"B19","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia","volume":"303","year":"1991","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/eurheartj\/ehx004","article-title":"Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia","volume":"38","author":"Tada","year":"2017","journal-title":"Eur Heart J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e018263","DOI":"10.1161\/JAHA.120.018263","article-title":"Patients with LDLR and PCSK9 gene variants experienced higher incidence of cardiovascular outcomes in heterozygous familial hypercholesterolemia","volume":"10","author":"Doi","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ajmg.a.30102","article-title":"Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial","volume":"128","author":"Marteau","year":"2004","journal-title":"A J Med Genet A."},{"key":"B24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.cjco.2020.12.006","article-title":"Patient perspectives regarding genetic testing for familial hypercholesterolemia","volume":"3","author":"Marchand","year":"2021","journal-title":"CJC Open."},{"key":"B25","doi-asserted-by":"publisher","first-page":"i1102","DOI":"10.1136\/bmj.i1102","article-title":"The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis","volume":"352","author":"Holland","year":"2016","journal-title":"BMJ."},{"key":"B26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/VHRM.S266249","article-title":"Familial hypercholesterolemia: a narrative review on diagnosis and management strategies for children and adolescents","volume":"17","author":"Tada","year":"2021","journal-title":"Vascul Health Risk Manag."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e030290","DOI":"10.1136\/bmjopen-2019-030290","article-title":"Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis","volume":"9","author":"Kinnear","year":"2019","journal-title":"BMJ Open."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/ajmg.a.32592","article-title":"Predictive genetic testing for cardiovascular diseases: impact on carrier children","volume":"146","author":"Meulenkamp","year":"2008","journal-title":"A J Med Genet A."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study","volume":"381","author":"Talmud","year":"2013","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jacc.2019.05.043","article-title":"Risk of premature atherosclerotic disease in patients with monogenic versus polygenic familial hypercholesterolemia","volume":"74","author":"Trinder","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"574474","DOI":"10.3389\/fgene.2020.574474","article-title":"Genetics of familial hypercholesterolemia: new insights","volume":"11","author":"Vrablik","year":"2020","journal-title":"Front Genet."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.982607\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T10:20:58Z","timestamp":1661422858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.982607\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":31,"alternative-id":["10.3389\/fcvm.2022.982607"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.982607","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"article-number":"982607"}}